In LNCaP prostate adenocarcinoma cells, treatment with 100 nM 25(OH)D3, alongside the CYP27B1 inhibitor genistein, resulted in a marked reduction in cell growth, suggesting that 25(OH)D3 can exert direct anti-proliferative effects [13]. This evidence concerns the gene CYP27B1 and prostate adenocarcinoma.